Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

NCT05873686 is registered in ClinicalTrials.gov with Nuvectis Pharma, Inc. as lead sponsor.

NCT NCT05873686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05873686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Lead sponsor
Nuvectis Pharma, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 26, 2023
Completion date
July 31, 2027
Enrollment
140 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, mesothelioma, non-small cell lung adenocarcinoma, non-small cell squamous lung cancer, nsclc (non-small cell lung cancer), renal cancer